07/09/2012
https://congress.gov...
"Finally, Mr. Chairman, we have a responsibility to ensure that patients come first and that it is their health and their livelihoods, not drug prices, which must be non-negotiable."
"I hope that moving forward we will not once again yield to the power of Big Pharma, instead, move to advance reasonable solutions that promote competition and achieve lower prices."
"over 200 device qualified in the first 3 years of the program. And some of those didn't actually show any useful benefits for patients and had important safety risks."
"The real angel investors in research and development for new cures in America are none other than American taxpayers."